2010
DOI: 10.1016/j.neuroimage.2010.04.034
|View full text |Cite
|
Sign up to set email alerts
|

Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

Abstract: Several studies have examined the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia. As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied. In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [(11)C]OMAR (JHU75528), we have shown its utility as a tracer for imaging human CB1 receptors … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

5
139
1

Year Published

2013
2013
2019
2019

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 179 publications
(145 citation statements)
references
References 57 publications
5
139
1
Order By: Relevance
“…[ 11 C]OMAR was developed by Horti and colleagues 13 and has been used in a clinical investigation of the CB1 receptor in schizophrenia. In that study, the subjects were almost exclusively men (n = 10 control subjects, all men; n = 6 schizophrenic subjects, one woman).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[ 11 C]OMAR was developed by Horti and colleagues 13 and has been used in a clinical investigation of the CB1 receptor in schizophrenia. In that study, the subjects were almost exclusively men (n = 10 control subjects, all men; n = 6 schizophrenic subjects, one woman).…”
Section: Discussionmentioning
confidence: 99%
“…These qualitative uptake patterns, as shown in the representative PET and coregistered MR images in Figure 2, are in very good agreement with previous imaging studies using other CB1 radiotracers. [8][9][10]13 After an initial peak attributable to high concentration of tracer in the vasculature relative to tissue, [ 11 C]OMAR concentrations in most brain regions reached a maximum at 20 to 25 minutes after injection with SUV ranging from 0.5 to 1.4. Kinetics of TACs was similar to that previously observed in nonhuman primates 12 with cerebral clearance generally faster than other CB1 ligands reported in humans.…”
Section: Arterial Plasma Measurementsmentioning
confidence: 99%
See 1 more Smart Citation
“…BP ND might not be obtained as k 3 /k 4 ratio for 18 F-AZAN, potentially because of the fact that these methods could not identify V ND (i.e., large variations of V ND among subjects). Unstable estimates of V ND by TTCM were also reported by other receptor radioligands such as 11 C-OMAR for CB1 (35) and 11 C-ABP688 for the metabotropic glutamate receptor subtype 5 (36). An alternative approach for BP ND (i.e., [target V T /corpus callosum V t ] 2 1), which appeared successful for PRGA, resulted in high TRV values for TTCM-C because of unacceptably large TRV values on the corpus callosum.…”
Section: Discussionmentioning
confidence: 60%
“…9 In addition, some studies have verified abnormalities in endocannabinoid ligands such as anandamide in patients with schizophrenia, 10,11 while others observed a potential antipsychotic property of CB1 receptor antagonists. 7,12 Neuroimaging findings have also associated cannabis use with progressive cortical thickness in areas rich in CB1 receptors during the initial years of schizophrenia. 13 This body of evidence suggests possible influences of the endocannabinoid system in the pathophysiology of the disorder.…”
Section: Introductionmentioning
confidence: 99%